Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone
| Autor: | Mehmet H. Koseoglu, Hulki Meltem Sönmez, Ekrem Muftuoglu, Gurhan Kadikoylu, Süleyman Demir, Orhan Ayyildiz, Zahit Bolaman |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
drug megadose age distribution diarrhea leukemia remission rash Gastroenterology etoposide hydroxyurea granulocyte colony stimulating factor cause of death flushing cytarabine dose response Streptococcus infection neurotoxicity Antineoplastic Combined Chemotherapy Protocols conjunctivitis Blastic phase fever clinical article liver dysfunction adult Remission Induction article Cytarabine prednisolone Combination chemotherapy clinical trial Hematology Middle Aged alpha interferon female Treatment Outcome carboplatin Vomiting mucosa inflammation Female medicine.symptom Chronic myelogenous leukemia medicine.drug blast cell crisis Adult medicine.medical_specialty azacitidine Leukemia Myeloid Chronic Nausea cladribine Blastic Phase vincristine Methylprednisolone mitoxantrone bone marrow hypoplasia meprednisone chronic myeloid leukemia Internal medicine Leukemia Myelogenous Chronic BCR-ABL Positive medicine pneumonia Humans controlled study human bacteremia survival time lung toxicity Mitoxantrone controlled clinical trial business.industry 5 aza 2' deoxycytidine leukopenia fludarabine Philadelphia 1 chromosome medicine.disease Survival Analysis Surgery Regimen febrile neutropenia imatinib High dose methylprednisolone validation process Blastic phase chronic myelogenous leukemia nausea and vomiting prognosis business Blast Crisis drug tolerability |
| Zdroj: | Haematologia. 32(1) |
| ISSN: | 0017-6559 |
| Popis: | Fourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methylprednisolone 1000 mg/day intravenously for 5 days. The patients' mean age was 52 +/- 10 (range 34-64) and Philadelphia chromosome was positive in all. Five patients (35%) achieved complete remission and four patients (28%) had a partial remission. Overall remission rate was 64%. The mean survival was 11.1 +/- 8.6 months (median 13) for all patients, 19.4 +/- 4.0 months (median 19) for those achieving a complete remission, 12.50 +/- 5.7 months (median 14) for patients with partial remission and 1.8 +/- 1.8 months (median 2) for the unresponsive patients. Two of 5 unresponsive patients died early after the second course of remission induction. The treatment regimen was generally well tolerated. Marrow hypoplasia was observed in 9 (64%) patients and 7 (50%) had febrile episodes. Non-myelosupressive toxicity of the regimen was acceptable. Nausea and vomiting were observed in 8 (57%) patients and 3 (21%) patients developed flushing due to cytosine arabinoside. These results suggest that the regimen with mitoxantrone, cytosine arabinoside and high dose methylprednisolone in remission-induction of blastic phase chronic myelogenous leukemia may be a valid option that may also improve overall prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|